Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › pomalidomide

pomalidomide

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of pomalidomide

38 trials tracked of pomalidomide: 8 in phase 3 or 4 and 4 with published results. The most-cited published study has 381 citations.

38Trials tracked
8Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 3 8 Phase 2 28 Phase 1 2
  1. Phase 3 Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma Completed · 381 cited
  2. Phase 3 Comparison of Pom and Dex in Subjects With RRMM Previously Treated With Len and a PI Dara/Pom/Dex vs Pom/Dex Completed · 324 cited
  3. Phase 3 Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma Completed · 162 cited
  4. Phase 3 Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients Completed · 31 cited
  5. Phase 3 An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma Completed
  6. Phase 3 Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma Completed
Show 32 more trials
  1. Phase 3 A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study Completed
  2. Phase 3 Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence Completed
  3. Phase 2 Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Completed
  4. Phase 2 CC-4047 and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Amyloidosis Completed
  5. Phase 2 Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia Completed
  6. Phase 2 A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis Completed
  7. Phase 2 A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM) Completed
  8. Phase 2 Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma Completed
  9. Phase 2 Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide Completed
  10. Phase 2 Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma Completed
  11. Phase 2 Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma Completed
  12. Phase 2 Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma Completed
  13. Phase 2 Pomalidomide in Treating Patients With Kaposi Sarcoma and Human Immunodeficiency Virus Infection Completed
  14. Phase 2 A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide. Completed
  15. Phase 2 Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma Completed
  16. Phase 2 A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma Completed
  17. Phase 2 Pomalidomide for Chronic Graft-versus-Host Disease Completed
  18. Phase 2 An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma Completed
  19. Phase 2 Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma Completed
  20. Phase 2 Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide Completed
  21. Phase 2 Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple Myeloma Completed
  22. Phase 2 MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma Completed
  23. Phase 2 Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet Completed
  24. Phase 2 CC-4047 With Gemcitabine for Untreated Advanced Carcinoma of the Pancreas Completed
  25. Phase 2 Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting Completed
  26. Phase 2 An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3) Completed
  27. Phase 2 A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia Completed
  28. Phase 2 A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors Completed
  29. Phase 2 Pomalidomide for Kaposi Sarcoma in People With or Without HIV Completed
  30. Phase 2 A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma Completed
  31. Phase 1 An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments Completed
  32. Phase 1 Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma Completed

Showing the 38 most-cited and recently-updated of 38 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
FDA Approves Pomalyst (pomalidomide) for Multiple Myeloma and Kaposi Sarcoma
Oncology FDA Approval
FDA Approves Pomalyst (pomalidomide) for Multiple Myeloma and Kaposi Sarcoma FDA approves new drug Pomalyst for multiple myeloma and Kaposi sarcoma.
The FDA approved Pomalyst (pomalidomide) for multiple myeloma in combination with dexamethasone after at least two prior therapies, and for …
The FDA approved Pomalyst (pomalidomide) for two conditions: multiple myeloma and Kaposi sarcoma. It offers a new option for patients who ha…
FDA May 2, 2026